MedPath

Novel Proteomics Test PROphet Shows Promise in Guiding Lung Cancer Immunotherapy Decisions

9 months ago2 min read
Share

Key Insights

  • The PROphet proteomics test demonstrates potential to enhance PD-L1 testing accuracy in lung cancer, helping identify patients who would benefit most from immunotherapy versus combination treatments.

  • Poor prognostic biomarkers like STK11 and KEAP1 mutations are emerging as important indicators for treatment selection, particularly in determining the need for triple combination therapy.

  • Liquid biopsies measuring circulating tumor DNA show promise in monitoring treatment response and could help guide real-time therapy adjustments in lung cancer patients.

The landscape of biomarker testing in lung cancer treatment is evolving beyond traditional PD-L1 expression analysis, with new proteomics-based approaches showing promising results in treatment selection. The plasma proteomics-based PROphet test has emerged as a potential complement to standard PD-L1 testing, offering improved accuracy in predicting immunotherapy response.

Advancing Beyond PD-L1 Testing Limitations

Current PD-L1 testing, while standard practice, has shown significant limitations. Dr. Luis Raez, Medical Director and Chief Scientific Officer of Memorial Cancer Institute, highlights that even among patients with PD-L1 expression above 50% - traditionally considered optimal candidates for immunotherapy - only about 40% respond to treatment.
The multicenter PROPHETIC trial has demonstrated that combining PD-L1 testing with plasma proteome analysis can better stratify patient outcomes. Notably, patients with high PD-L1 expression (≥50%) who tested PROphet-negative showed significantly improved survival with chemoimmunotherapy compared to immunotherapy alone (HR, 0.23; 95% CI, 0.1-0.51, P < .0003).

Role of Poor Prognostic Biomarkers

Research has identified several poor prognostic biomarkers that are reshaping treatment approaches. Patients with STK11 or KEAP1 mutations typically show poor response to single-agent immunotherapy. For these patients, data from the POSEIDON trial suggests that a triple combination approach using anti-CTLA-4 and anti-PD-L1 inhibitors plus chemotherapy may be more beneficial.

Emerging Role of Liquid Biopsies

Circulating tumor DNA (ctDNA) monitoring through liquid biopsies represents another promising biomarker approach. Dr. Raez explains that ctDNA levels correlate with tumor presence and treatment response, potentially allowing for real-time treatment adjustments. Declining ctDNA levels may indicate successful immunotherapy treatment, while stable or increasing levels might suggest the need to add chemotherapy to the treatment regimen.

Moving Toward Precision Immunotherapy

The integration of these new biomarker approaches represents a crucial step toward more personalized immunotherapy strategies. "We need to tailor immunotherapy approaches better because we want something more cost effective and less toxic for patients," emphasizes Dr. Raez. This multi-biomarker approach could help overcome the current "one-size-fits-all" approach to immunotherapy, leading to more precise treatment selection and improved patient outcomes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related News

© Copyright 2025. All Rights Reserved by MedPath